|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 2 | Morphology observation for surface orange peel and fracture in tension sample of aluminum-alloy sheet and characterization of nano hardness显示文摘The tension property of aluminum-alloy sheet with different microstructures is measured,and the surface and tension fracture morphology of tension sample with and without orange peel are observed by using scanning electron microscope(SEM).Surface roughness and nano hardness of tension sample are measured.The results show that the average elongation of the samples with orange peel is lower than that without orange peel;especially the r value of perpendicular to the rolling direction is much lower than that without orange peel.The tension surface of the orange peel samples is very rough;various parameters of surface roughness are higher.Under the observation of SEM,a wider sliding band with a micro crack on the surface of orange peel sample can be found.The various parameters of surface roughness without orange peel sample are near to zero,the sliding band is narrow and without micro cracks.The dimple width in tensile fracture of orange peel sample is larger than that without orange peel sample,but shear lip is narrower.The nano hardness testing results show that samples with orange peel behave high elastic modulus,high hardness,and high maximum load,but low plastic deformation depth.These mentioned features can completely describe surface and fracture morphology of tension samples with orange peel. | Ma Mingtu Mei Huasheng Lu Hongzhou Yang Hongya Wu Emei Zhou Mingbo | 2012 | Engineering Sciences2012，10，6： | 4 |
| 3 | Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib:a propensity score matching analysis显示文摘Objective: Although superior clinical benefits of epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors(TKIs) in the treatment of advanced non-small-cell lung cancer(NSCLC) had been reported,the survival difference between exon 19 deletion(Del19) and exon 21 Leu858 Arg substitution(L858 R) remains controversial.The purpose of this study is to investigate the differences in progression-free survival(PFS) and overall survival(OS) between different EGFR mutant subtypes among advanced NSCLC patients receiving gefitinib.Methods: There were 204 advanced NSCLC patients with EGFR mutations treated with gefitinib were enrolled in this retrospective cohort study.Patients were divided into the EGFR Del19 group and the L858 R mutated group according to their mutant subtype.Propensity score matching(PSM) was conducted by using a nearest-neighbor algorithm(1:1) to adjust for demographical and clinical covariates.Survival curves were constructed with the Kaplan-Meier method and compared by using the log-rank test.Results: The PFS in Del19 group was similar to that in the L858 R group [before PSM 8.6 vs.7.2 months,P=0.072; after PSM 7.3 vs.7.2 months,P=0.155].No differences were detected in OS between the L858 R and the Del19 group(before PSM 17.8 vs.13.1 months,P=0.253; after PSM 16.9 vs.13.1 months,P=0.339).The Del19 group was significantly younger compared with the L858 R mutation group in age(P=0.015).Conclusions: No significant difference was found in the PFS or OS between the Del19 and L858 R mutant NSCLC patients receiving gefitinib.The age gap might contribute to the survival differences between Del19 and L858 R groups.PSM is of important value to the elimination of potential bias. | Minglei Zhuo Qiwen Zheng Jun Zhao Meina Wu Tongtong An Yuyan Wang Jianjie Li Shuhang Wang Jia Zhong Xue Yang Hanxiao Chen Bo Jia Zhi Dong Emei Gao JingjingWang Ziping Wang | 2017 | Chinese Journal of Cancer Research2017，29，6： | 4 |
| 4 | Oral,but not transdermal,administration of estrogens lowers tissue-type plasminogen activator levels in humans without affectiong endothelial synthesis显示文摘 | Gooren LJ Emeis JJ | 2000 | Arterioscler Thromb Vasc Biol2000，20，： | 1 |
| 5 | C-reactive protein in healthy subjects:associations with obesity,insulin resistance and endothelial dysfunction:Potential role for cytokines originating from adipose tissue显示文摘 | Yudkin JS Stehouwer CDA Emeis JJ | 1999 | Arterioscler Thromb Vase Biol1999，19，4： | 1 |
| 6 | Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease显示文摘 | Padr 6 T Emeis JJ Steins M | 1995 | Arterioscler Thromb Vasc Bio11995，15，7： | 1 |
| 7 | Hormone replacement therapy显示文摘 | Kooistra T J J Emeis | 1999 | Curr Opin Chem Bio11999，3，4： | 1 |
| 8 | Sea-surface temperatures and the history of monsoon upwelling in the northwest Arabian sea during the last 500 000 years 显示文摘 | EMEIS K C ANDERSON D M DOOSE H | 1995 | Quaternary Research1995，43，： | 1 |
| 9 | Vaginal birth after cesarean: new insights on maternal and neonatal outcomes 显示文摘 | Gusie JM Denman MA Emeis C | 2010 | Obstet Gynecol2010，115，： | 1 |
| 10 | Vaginal birth after cesarean: new insights on maternal and neonatal outcomes显示文摘 | Guise JM Denman MA Emeis C | 2010 | Obstet Gynecol2010，115，6： | 1 |
| 11 | C-reactive protein in healthy subjects:associations with obesity,insulin resistance,and endothelial dysfunction:a potential role for cytokines originating from adipose tissue显示文摘 | Yudkin JS Stehouwer CD Emeis JJ | | 0，，04： | 1 |
| 12 | Determination of integrated molar extinction coefficients for infrared absorption bands of pyridine adsorbed on solid acid catalysts 显示文摘 | EMEIS C A | 1993 | Journal of Catalysis1993，141，2： | 1 |
| 13 | Determination of integrated molar extinction coefficients for infrared absorption bands of pyridine adsorbed on solid acid catalysts显示文摘 | Emeis C A | | 0，，02： | 1 |
| 14 | A guide to mu- rine coagulation factor structure, function, assays, and genetic al- terations 显示文摘 | Emeis J J Jirouskova M Muehitsch E M | 2007 | J Thromb Haemost2007，，： | 1 |
| 15 | Stable nitrogen isotopic ratios of sinking particles and sediments from the northern Indian Ocean显示文摘 | GAYE-HAAKE B LAHAJNAR N EMEIS K C | 2005 | Marine Chemistry2005，96，： | 1 |
| 16 | Long-term a-nalysis of peritoneal plasminogen activator activity and adhe-sion formation after surgical trauma in the rat model显示文摘 | Bakkum EA Emeis JJ Dalmeijer RA | 1996 | Fertil Steril1996，66，6： | 1 |
| 17 | Regulation of the acute release of tissue-type plasminogen activator from endothelium by coagulation products显示文摘 | Emeis JJ | 1992 | Ann NY Acad Sci1992，667，： | 1 |
| 18 | Biochemical corroboration of endothelial involvcment in severe preeclampsia显示文摘 | Friedman SA Eyal S Emeis JJ | 1995 | Am J Obstct Gyncol1995，172，： | 1 |
| 19 | Explanation of the matrix-induced chromatographic response enhancement of organophosphorus pesticides during open tubular column gas chromatography with splitless or hot on-column injection and flame photometric detection显示文摘 | Emey D R Gillespie A M Gilvydis D M | 1993 | J Chromatogr1993，638，1： | 1 |
| 20 | C-reactive protein in healthy subjects:associations with obesity,insulin resistance,and endothelial dysfunction:a potential role for cytokines originating from adipose tissue显示文摘 | Yudkin JS Stehouwer CD Emeis JJ | 1999 | Arterioscler Thromb Vasc Biol1999，19，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员